Clinical trial NCT04740424: FS222 First in Human Study in Patients With Advanced Malignancies
Official title: A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Advanced Cancer
Metastatic Cancer
Keywords: Immuno-oncology
bispecific antibody
dose escalation
cohort expansion
CD137
PD-L1
F-star
4-1BB
Immunotherapy
Lead sponsor: invoX Pharma Limited
Sponsor class: INDUSTRY
First posted: 2021-02-05
Enrollment: 177
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will be conducted in adult participants diagnosed with advanced tumours to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS222. This is a Phase 1, multi-center, open label, multiple-dose, first in human study, designed to systematically assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS222 in participants with advanced tumours. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years.
* Participants with histologically or cytologically confirmed, locally advanced, unresectable or metastatic solid tumours for whom standard therapy has proven to be ineffective, intolerable or is considered inappropriate. This criterion does not apply to the PK/PD expansion cohort, where tumour-specific criteria will apply instead.
* No more than 1 line of prior therapy with ICB treatment. Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
* Participants who have received prior ICB, or any concurrent chemotherapy, radiotherapy, investigational, biologic or hormonal therapy for cancer treatment may be eligible for enrolment following a washout period.
* Participants who have received prior anti-PD-L1 therapy are eligible if PD-L1 therapy was discontinued ≥6 months prior to entry into the study.
* Participants who have failed a prior ICB regimen should document it.
* Measurable disease. Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
* Eastern Cooperative Oncology Group Performance Status ≤1.
* The participant agrees to undergo a mandatory pre-treatment and on-treatment biopsy of the tumour. Certain exceptions apply.
* Highly effective contraception.
* Willing and able to provide written informed consent.

Exclusion Criteria:

* Participants with clinically relevant COVID-19 disease risk will be excluded from enrolment during the COVID-19 pandemic.
* Concurrent enrolment in another clinical study with the exception of non-interventional/observational studies or the follow-up period of an interventional study.
* Prior treatment with CD137 agonist mAb or other experimental agonists.
* For participants who have received prior ICB, participants must not have received more than 1 line of prior treatment with ICB(s). Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
* Participants with active autoimmune disease.
* Receipt of any live virus vaccine within 30 days prior to the first dose of study drug.
* Receipt of a live attenuated vaccine within 30 days prior to the first dose of study drug.
* History of uncontrolled intercurrent illness.
* Psychological, familial, sociological or geographical conditions that do not permit compliance with the protocol.
* Judgment by the investigator that the participant is unsuitable to participate in the study, and the participant is unlikely to comply with study procedures, restrictions and requirements.
* Significant laboratory abnormalities.
* Known infections.
* Uncontrolled CNS metastases, primary CNS tumours with CNS metastases as only measurable disease. Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
* Prior history of any Grade ≥3 irAE that has not improved to Grade ≤1, except for endocrine deficiencies that are managed by HRT; significant treatment-related cytokine release syndrome; systemic inflammatory response syndrome.
* Current use of immunosuppressive agents, prior organ transplantation requiring immunosuppression, hypersensitivity or intolerance to mAb or their excipients, or persisting toxicity related to prior therapy of Grade \>1 NCI CTCAE Version 5.0 .

Primary outcomes:
measure: Presence of adverse events (AEs) and serious adverse events (SAEs)
timeFrame: 15 months
measure: Determination of a maximum tolerated dose (MTD) by evaluation of DLTs
timeFrame: 28 days
measure: Determination of a recommended Phase 2 dose (RP2D) by evaluation of DLTs
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Tbilisi
country: Georgia
facility: Arensia Exploratory Medicine, LLC
city: Bucharest
country: Romania
facility: Prof. Dr. Alexandru Trestioreanu Oncologic Institute
city: Bucharest
country: Romania
facility: "Dr. Carol Davila" Nephrology Clinical Hospital
city: Cluj-Napoca
country: Romania
facility: Prof Dr I Chiricuta Institute of Oncology
city: Pamplona
country: Spain
facility: Clinica Universidad Navarra
state: Navarra
city: Barcelona
country: Spain
facility: NEXT - Hospital Quironsalud Barcelona
city: Barcelona
country: Spain
facility: Hospital Universitari Vall D'Hebron
city: Barcelona
country: Spain
facility: Hospital Clinic de Barcelona
city: Barcelona
country: Spain
facility: Institut Catala d'Oncologia de Badalona
city: Las Palmas De Gran Canaria
country: Spain
facility: Complejo Hospitalario Universitario Insular-Materno Infantil
city: Madrid
country: Spain
facility: Instituto de Investigación Sanitaria Fundación Jimenez Díaz
city: Madrid
country: Spain
facility: Hospital Universitario 12 De Octubre
city: Madrid
country: Spain
facility: NEXT - Hospital Universitario Quironsalud Madrid
city: Majadahonda
country: Spain
facility: Hospital Universitario Puerta de Hierro - Majadahonda
city: Seville
country: Spain
facility: Universitary Hospital Virgen Macarena
city: Valencia
country: Spain
facility: Hospital Clinico Universitario de Valencia
Study officials:
References: